Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Pulmonary Tuberculosis
NCT06199921Phase 2Recruiting
- Sponsor
- Obafemi Awolowo University Teaching Hospitals Complex
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin in pulmonary tuberculosis (TB) (4 arms), sponsored by Obafemi Awolowo University Teaching Hospitals Complex. Primary endpoints: Proportion of participants with grade 3 or higher adverse events at 24 weeks, TB disease-free survival at six months post randomization at 6 months and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06199921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199921.